Literature DB >> 31801041

Initial renal histology and early response predict outcomes of Brazilian lupus nephritis patients.

G Vajgel1,2, C B L Oliveira1,3, D M N Costa1,3, M A G M Cavalcante1, L M Valente1, R Sesso4, S Crovella2,5, G M Kirsztajn4, P Sandrin-Garcia2,5.   

Abstract

OBJECTIVE: We analyzed baseline and follow-up characteristics related to poorer renal outcomes in a Brazilian cohort of admixture race patients with lupus nephritis.
METHODS: Overall, 280 outpatients with a diagnosis of systemic lupus erythematosus and previous kidney biopsy of lupus nephritis were recruited from August 2015 to December 2018 and had baseline laboratory and histologic data retrospectively analyzed; patients were then followed-up and data were recorded. The main outcome measure was the estimated glomerular filtration rate at last follow-up. Secondary analyses assessed the impact of initial kidney histology and treatment in long-term kidney survival.
RESULTS: Median duration of lupus nephritis was 60 months (interquartile range: 27-120); 40 (14.3%) patients presented progressive chronic kidney disease (estimated glomerular filtration rate <30 and ≥10 ml/min/1.73 m2) or end-stage kidney disease at last visit. Adjusted logistic regression analysis showed that class IV lupus nephritis (odds ratio 14.91; 95% confidence interval 1.77-125.99; p = 0.01) and interstitial fibrosis ≥25% at initial biopsy (odds ratio 5.87; 95% confidence interval 1.32-26.16; p = 0.02), lack of complete or partial response at 12 months (odds ratio 16.3; 95% confidence interval 3.74-71.43; p < 0.001), and a second renal flare (odds ratio 4.49; 95% confidence interval 1.10-18.44; p = 0.04) were predictors of progressive chronic kidney disease. In a Kaplan-Meier survival curve we found that class IV lupus nephritis and interstitial fibrosis ≥25% were significantly associated with end-stage kidney disease throughout follow-up (hazard ratio 2.96; 95% confidence interval 1.3-7.0; p = 0.036 and hazard ratio 4.96; 95% confidence interval 1.9-12.9; p < 0.0001, respectively).
CONCLUSION: In this large cohort of admixture race patients, class IV lupus nephritis and chronic interstitial damage at initial renal biopsy together with non-response after 1 year of therapy and relapse were associated with worse long-term renal outcomes.

Entities:  

Keywords:  Nephritis; renal lupus; systemic lupus erythematosus

Mesh:

Year:  2019        PMID: 31801041     DOI: 10.1177/0961203319890681

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

Review 1.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

2.  Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients.

Authors:  Keqian Du; Xuecheng Zhang; Junmei Feng; Sijie Zhong; Jun Qi; Zhiming Lin
Journal:  Clin Rheumatol       Date:  2022-07-19       Impact factor: 3.650

3.  Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience.

Authors:  Emine Duran; Tolga Yıldırım; Arzu Taghiyeva; Emre Bilgin; Mustafa Arıcı; Emine Arzu Sağlam; Seza Özen; Meral Üner; Yunus Erdem; Umut Kalyoncu; Ali Ihsan Ertenli
Journal:  Lupus       Date:  2022-06-03       Impact factor: 2.858

4.  Predictors of Early Response, Flares, and Long-Term Adverse Renal Outcomes in Proliferative Lupus Nephritis: A 100-Month Median Follow-Up of an Inception Cohort.

Authors:  Eleni Kapsia; Smaragdi Marinaki; Ioannis Michelakis; George Liapis; Petros P Sfikakis; John Boletis; Maria G Tektonidou
Journal:  J Clin Med       Date:  2022-08-26       Impact factor: 4.964

Review 5.  The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations.

Authors:  Evandro Mendes Klumb; Morton Scheinberg; Viviane Angelina de Souza; Ricardo Machado Xavier; Valderilio Feijo Azevedo; Elizabeth McElwee; Mariana Rico Restrepo; Odirlei André Monticielo
Journal:  Lupus       Date:  2021-07-13       Impact factor: 2.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.